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Drug Selection
via Joint Push and Learning to Rank
Yicheng He∗, Junfeng Liu∗, and Xia Ning‡
Abstract—Selecting the right drugs for the right patients is a primary goal of precision medicine. In this manuscript, we consider the
problem of cancer drug selection in a learning-to-rank framework. We have formulated the cancer drug selection problem as to
accurately predicting 1). the ranking positions of sensitive drugs and 2). the ranking orders among sensitive drugs in cancer cell lines
based on their responses to cancer drugs. We have developed a new learning-to-rank method, denoted as pLETORg, that predicts drug
ranking structures in each cell line via using drug latent vectors and cell line latent vectors. The pLETORg method learns such latent
vectors through explicitly enforcing that, in the drug ranking list of each cell line, the sensitive drugs are pushed above insensitive
drugs, and meanwhile the ranking orders among sensitive drugs are correct. Genomics information on cell lines is leveraged in
learning the latent vectors. Our experimental results on a benchmark cell line-drug response dataset demonstrate that the new
pLETORg significantly outperforms the state-of-the-art method in prioritizing new sensitive drugs.
Index Terms—Drug Selection, Learning to Rank
F
1 INTRODUCTION
S ELECTING the right drugs for the right patients is aprimary goal of precision medicine [1]. An appealing
option for precision cancer drug selection is via the pan-
cancer scheme [2] that examines various cancer types to-
gether. The landscape of cancer genomics reveals that var-
ious cancer types share driving mutagenesis mechanisms
and corresponding molecular signaling pathways in several
core cellular processes [3]. This finding has motivated the
most recent clinical trials (e.g., the Molecular Analysis for
Therapy Choice Trial at National Cancer Institute1) to iden-
tify common targets for patients of various cancer types and
to prescribe same drug therapy to such patients. Such pan-
cancer scheme is also well supported by the strong pan-
cancer mutations [4] and copy number variation [5] patterns
observed from The Cancer Genomics Atlas2 project. The
above pan-cancer evidence from theories and practices lays
the foundation for joint analysis of multiple cancer cell lines
and their drug responses to prioritize and select sensitive
cancer drugs.
Another appealing option for precision cancer drug se-
lection is via the popular off-label drug use [6] (i.e., the use
of drugs for unapproved therapeutic indications [7]). This is
due to the fact that some aggressive cancer types have very
limited existing therapeutic options, while conventional
drug development for those cancers, and also in general,
has been extremely time-consuming, costly and risky [8].
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However, a key challenge for off-label drug use is the lack of
knowledge base of preclinical and clinical evidence, hence,
the guidance for drug selection in practice [9].
In this manuscript, we present a new computational
cancer drug selection method – joint push and LEarning TO
Rank with genomics regularization (pLETORg). In pLETORg,
we formulate the problem of drug selection based on cell
line responses as a learning-to-rank [10] problem, that is, we
aim to produce accurate drug orderings (in terms of drug
sensitivity) in each cell line via learning, and thus prioritize
sensitive drugs in each cell line. This corresponds to the ap-
plication scenario in which drugs need to be prioritized and
selected to treat a given cell line/patient. Drug sensitivity
here represents the capacity of drugs for reduction in cancer
cell proliferation. Cell line responses to drugs reflect drug
sensitivities on the cell lines, and thus, we use the concepts
of drug sensitivity and cell line response in this manuscript
exchangeably.
To induce correct ordering of drugs in each cell line
in terms of drug sensitivity, for each involved drug and
cell line, in pLETORg, we learn a latent vector and score
drugs in each cell line using drug latent vectors and the
corresponding cell line latent vector. We learn such latent
vectors through explicitly enforcing and optimizing that, in
the drug ranking list of each cell line, the sensitive drugs
are pushed above insensitive drugs, and meanwhile the
ranking orders among sensitive drugs are correct, where
the ranking position of a drug in a cell line is determined
by the drug latent vector and cell line latent vector. We
simultaneously learn from all the cell lines and their drug
ranking structures. In this way, the structural information of
all the cell lines can be transferred across and leveraged dur-
ing the learning process. We also use genomics information
on cell lines to regularize the latent vectors in learning to
rank. Fig. 1 demonstrates the overall scheme of the pLETORg
method.
The new pLETORg is significantly different from the ex-
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Fig. 1: pLETORg scheme overview
isting computational drug selection methods. Current com-
putational efforts for precision cancer drug selection [11]
are primarily focused on using regression methods (e.g.,
kernel based methods [12], [13], matrix factorization [14],
[15], network-based similarity aggregation [16]) to predict
drug sensitivities (e.g., in GI50 3, IC50 4) numerically, and se-
lecting drugs with optimal sensitivities in each cell line [17].
For example, in Menden et al. [18], cell line features (e.g.,
sequence variation, copy number variation) and drug fea-
tures (e.g., physicochemical properties) are jointly used to
train a neural network that predicts drug sensitivities in
IC50 values. Drug selection has also been formulated as
a classification problem. For example, in Stanfield et al. [19],
cell line profiles, and drug sensitive and resistant profiles
are generated from heterogeneous cell line-protein-drug
interaction networks to score drugs in cell lines. The scores
are compared with a threshold to classify whether the drugs
are sensitive in the cell lines. Another focus of the existing
methods is on effectively using genomics information on
cell lines and features on drugs to improve regression [15],
[12]. For example, in Ammad-ud-din et al. [20], a kernel is
constructed on each type of drug and cell line features to
measure their respective similarities, and drug sensitivity is
predicted from the combination of projected drug kernels
and cell line kernels.
The existing regression based methods for drug selection
may suffer from the fact that the regression accuracy is
largely affected by insensitive drugs, and therefore, accurate
drug sensitivity regression does not necessarily lead to
accurate drug selection (prioritization). This is because in
regression models, in order to achieve small regression er-
rors, the majority of drug response values in a cell line needs
to be fit well. However, when insensitive drugs constitute
the majority in each cell line, which is becoming common
as the advanced technologies are enabling screenings over
large collections of small molecules (e.g., in the Library of
3. https://dtp.cancer.gov/databases tools/docs/compare/compare
methodology.htm
4. https://www.ncbi.nlm.nih.gov/books/NBK91994/
Integrated Network-Based Cellular Signatures (LINCS) 5), it
is very likely that the regression sacrifices its accuracies on
a very few but sensitive drugs in order to achieve better ac-
curacies on the majority insensitive drugs, and thus smaller
total errors on all drugs overall. This situation is even more
likely when the cell line response values on sensitive drugs
follow a very different distribution, and thus appear like
outliers [21], than that from insensitive drugs, which is also
very often the case. Fig. 2 presents a typical distribution of
cell line (LS123 from Cancer Therapeutics Response Portal
(CTRP v2) 6) responses to drugs. In Fig. 2, lower cell line
response scores indicate higher drug sensitivities. It is clear
in Fig. 2 that top most sensitive drugs (in red in the figure)
have sensitivity values of a different distribution than the
rest. When cell line responses on sensitive drugs cannot be
accurately predicted by regression models, it will further
lead to imprecise drug selection or prioritization (e.g., sen-
sitive drugs may be predicted as insensitive).
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Fig. 2: Exemplar cell line response score distribution
Instead, ranking methods represent a more natural and
effective alternative so as to directly prioritize and select
drugs. In order to enable drug selection, in the end, a
sorted/ranking order of drugs needs to be in place. Accurate
predicted cell line response values on drugs can serve to
sort/rank drugs in order. However, any other scores can
also serve the purpose as long as they produce desired drug
orders. This provides the opportunity for learning-to-rank
methods for drug selection, which focus on learning the
drug ranking structures directly (via using certain scores
to sort drugs). Actually, regression based drug selection
corresponds to point-wise learning to rank, which has been
demonstrated [22] to perform suboptimally compared to
pairwise and listwise ranking methods. Detailed literature
review on learning to rank is available in Section 2 (addi-
tional references are available in Section S8 in the supple-
mentary materials).
The rest of the manuscript is organized as follows.
Section 2 presents the literature review on learning-to-rank
methods. Section 3 presents the new pLETORg method. Sec-
tion 4 presents the materials used in experiments. Section 5
presents the experimental results. Section 6 presents the
conclusions.
2 LITERATURE REVIEW ON LEARNING TO RANK
Learning to Rank (LETOR) [23] focuses on developing ma-
chine learning methods and models that can produce ac-
curate rankings of interested instances, rather than using
5. http://www.lincsproject.org/
6. https://portals.broadinstitute.org/ctrp/
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pre-defined scoring functions to sort the instances. LETOR
is the key enabling technique in information retrieval [24].
Existing LETOR methods fall into three categories: 1). point-
wise methods [22], which learn a score on each individual
instance that will be used to sort/rank all the instances;
2). pairwise methods [25], which optimize pairwise ranking
orders among all instances to induce good ranking orders
among the instances; and 3) listwise methods [26], which
model the full combinatorial structures of ranking lists.
It has been demonstrated [22] that pairwise and listwise
ranking methods outperform pointwise methods in general.
This is because in pairwise and listwise methods, the order-
ing structures among instances are leveraged in learning,
whereas in pointwise methods, no ordering information is
used. Moreover, listwise methods are more computationally
challenging than the others, due to the combinatorial nature
of ranking lists as a whole. Thus, pairwise methods are
the choice in many ranking problems, given the trade-off
between ranking performance and computational demands.
The idea of using LETOR approaches to prioritize com-
pounds has also drawn some recent attention [27], [28], [29].
For example, Agarwal et al. [30] developed bipartite rank-
ing [31] to rank chemical structures for Structure-Activity-
Relationship (SAR) modeling such that active compounds
and inactive compounds are well separated in the ranking
lists. Liu and Ning [29] developed a ranking method with
bi-directional powered push strategy to prioritize selective
compounds from multiple bioassays. However, LETOR has
not been widely used in prioritizing drugs in computational
medicine domain.
In LETOR, a particular interest is to improve the per-
formance on the top of the ranking lists [32], [33], that is,
instead of optimizing the entire ranking structures, only the
top of the ranking lists will be optimized (i.e., to rank the
most relevant instances on top), while the rest of the ranking
lists, particularly the bottom of the ranking lists, is of little
interest. An effective technique to enable good ranking
performance on top in LETOR is via push [34], [35], [27]. The
key idea is to explicitly push relevant instances onto top
during optimization. Various optimization algorithms are
developed to deal with the non-trivial objective functions
when push is involved [25], [36].
3 METHODS
We propose the joint push and LEarning TO Rank with
genomics regularization (pLETORg) for drug prioritization
and selection. The pLETORg method learns and uses latent
vectors of drugs and cell lines to score each drug in a cell
line, and ranks the drugs based on their scores (Section 3.1).
During the learning process, pLETORg explicitly pushes the
sensitive drugs on top of the ranking lists that are produced
by the prospective latent vectors (Section 3.2), and optimizes
the ranking orders among sensitive drugs (Section 3.3)
simultaneously. In addition, pLETORg uses genomics infor-
mation on cell lines to constrain cell line latent vectors
(Section 3.4). The following sections describe pLETORg in
detail. The supplementary materials are available online7.
Table 1 presents the key notations used in the
manuscript. In this manuscript, drugs are indexed by i and
7. http://cs.iupui.edu/∼liujunf/projects/CCLERank/
TABLE 1: Notations
notation meaning
Cp cell line p
di drug i
d
+/d− a sensitive/insensitive drug in a cell line
C+p/C−p the set of sensitive/insensitive drugs in Cp
n+p/n−p the size of C+p/C−p
up/vi latent vector for cell line Cp/drug di
m/n the total number of cell lines/drugs
j, and cell lines are indexed by p and q. We use d+/d−
to indicate sensitive/insensitive drugs (sensitivity labeling
will be discussed later in Section 4.1.2) in a certain cell line,
for example, d+i ∈ Cp or di ∈ C+p indicates that drug di
is sensitive in cell line Cp. Cell line is neglected when no
ambiguity arises.
3.1 Drug Scoring
We model that the ranking of drugs in terms of their
sensitivities in a cell line is determined by their latent scores
in the cell line. The latent score of drug di in cell line Cp,
denoted as fp(di), is estimated as the dot product of di’s
latent vector vi ∈ Rl×1 and Cp’s latent vector up ∈ Rl×1,
where l is the latent dimension, that is,
fp(di) = f(di, Cp) = uTpvi, (1)
where f(d, C) is the dot-product scoring function, and the
latent vectors up and vi will be learned. Then all the drugs
are sorted based on their scores in Cp. The most sensitive
drugs in a cell line will have the highest scores and will be
ranked higher than insensitive drugs. Thus, drug selection
in pLETORg is to identify optimal drug and cell line latent
vectors that together produce preferable cell line-specific
drug scores and rankings. Note that in pLETORg, we look
for scores fp(di) as long as they can produce correct drug
rankings, but these scores are not necessarily identical to
drug sensitivity values (e.g., shifted drug sensitivity values
can also produce perfect drug rankings). In addition, the
scoring scheme is similar to that used in some matrix factor-
ization approaches in recommender systems research [37].
However, the latent vectors u and v will be learned via
learning the top ranking structures (as will be discussed
later), not through factorizing the cell line-drug matrix.
3.2 Pushing up Sensitive Drugs
To enforce the high rank of sensitive drugs, we leverage
the idea of ranking with push [35]. The key idea is to
quantitatively measure the ranking positions of drugs, and
look for ranking models that can optimize such quantita-
tive measurement so as to rank sensitive drugs high and
insensitive drugs low. In pLETORg, we use the height of an
insensitive drug d−i in Cp, denoted as hf (d−i , Cp), to measure
its ranking position in Cp [35] as follows,
hf (d
−
i , Cp) =
∑
d
+
j∈C+p
I(fp(d+j ) ≤ fp(d−i )), (2)
where C+p is the set of sensitive drugs in cell line Cp, f is
the drug scoring function (Equation 1), fp(d+j ) and fp(d
−
i )
are the scores of d+j and d
−
i in Cp, respectively, and I(x) is
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the indicator function (I(x) = 1 if x is true, otherwise 0).
Essentially, hf (d−i , Cp) is the number of sensitive drugs that
are ranked below the insensitive drug d−i in cell line Cp by
the scoring function f .
To push sensitive drugs higher in a cell line, it is to
minimize the total height of all insensitive drugs in that
cell line To push sensitive drugs higher in a cell line, the
total height of all insensitive drugs in that cell line should
be minimized (i.e., minimize the total number of sensitive
drugs that are ranked below insensitive drugs). Thus, for all
the cell lines, it is to minimize their total heights, denoted as
P ↑f , that is,
P ↑f =
m∑
p=1
1
n+pn
−
p
∑
d
−
i∈Cp
hf (d
−
i , Cp), (3)
where m is the number of cell lines, and n+p and n
−
p are the
numbers of sensitive and insensitive drugs in cell line Cp.
The normalization by n+p and n
−
p is to eliminate the effects
from different cell line sizes.
3.3 Ranking among Sensitive Drugs
In addition to pushing sensitive drugs on top of insensitive
drugs, we also consider the ranking orders among sensitive
drugs in order to enable fine-grained prioritization among
sensitive drugs. Specifically, we use di R dj to represent
that di is ranked higher than dj in the relation R. We use
concordance index (CI) to measure drug ranking structures
compared to the ground truth, which is defined as follows,
CI({di}, C, f) = 1|{di C dj}|
∑
diCdj
I(di f dj), (4)
where {di} is the set of drugs in cell line C, {di C dj} is
the set of ordered pairs of drugs in cell line C (di C dj
represents that di is more sensitive, and thus ranked higher,
than dj in C), f is the scoring function (Equation 1) that
produces an estimated drug ranking, di f dj represents
that di is ranked higher than dj by f , and I is the indicator
function. Essentially, CI measures the ratio of correctly
ordered drug pairs by f among all possible pairs. Higher
CI values indicate better ranking structures.
To promote correct ranking orders among sensitive
drugs in all the cell lines, we minimize the objective O+f ,
defined as the sum of 1 − CI values (i.e., the ratio of mis-
ordered drug pairs among all pairs) over the sensitive drugs
of all the cell lines, as follows,
O+f =
m∑
p=1
[1− CI({d+i }, Cp, f)]
=
m∑
p=1
1
|{d+i Cp d+j }|
∑
d
+
iCpd+j
I(d+i ≺f d+j ).
(5)
3.4 Overall Optimization Problem for pLETORg
Overall, we seek the cell line latent vectors and drug latent
vectors that will be used in drug scoring function f (Equa-
tion 1) such that for each cell line, the sensitive drugs will be
ranked on top and in right orders using the latent vectors.
In pLETORg, such latent vectors are learned by solving the
following optimization problem:
min
U,V
Lf = (1− α)P ↑f + αO+f +
β
2
Ruv +
γ
2
Rcsim, (6)
where Lf is the overall loss function; P ↑f and O+f
are defined in Equation 3 and Equation 5, respectively;
U = [u1,u2, · · · ,um] and V = [v1,v2, · · · ,vn] are the la-
tent vector matrices for cell lines and drugs, respectively
(U ∈ Rl×m, V ∈ Rl×n, where l is the latent dimension);
α (α ∈ [0, 1]) is a weighting parameter to control the
contribution from push (i.e., P ↑f ) and ranking (i.e., O
+
f ); β
and γ are regularization parameters (β ≥ 0, γ ≥ 0) on the
two regularizers Ruv and Rcsim, respectively.
In Problem 6, Ruv is a regularizer on U and V to prevent
overfitting, defined as
Ruv =
1
m
‖U‖2F +
1
n
‖V ‖2F , (7)
where ‖X‖F is the Frobenius norm of matrix X . Rcsim is a
regularizer on cell lines to constrain cell line latent vectors,
defined as
Rcsim =
1
m2
m∑
p=1
m∑
q=1
wpq‖up − uq‖22, (8)
where wpq is the similarity between Cp and Cq that is
calculated using genomics information of the cell lines (e.g.,
gene expression information). The underlying assumption is
that if two cell lines have similar patterns in their genomics
data (i.e., large wpq), they will be similar in their cell line
response patterns, and thus similar latent vectors [17].
The Problem 6 involves an indicator function (in Equa-
tion 2, 4), which is not continuous or smooth. Thus, we use
the logistic function as its surrogate [34], that is,
I(x ≤ y) ≈ log[1 + exp(−(x− y))] = − log σ(x− y), (9)
where σ(x) is a sigmoid function, that is, σ(x) = 11+exp(−x) .
The optimization algorithm for pLETORg optimization is
presented in Algorithm S1 in supplementary materials. We
use alternating minimization with gradient descent (details
in Section S2 in supplementary materials) to solve the opti-
mization Problem 6.
Since the number of drugs pairs is quadratically larger
than the number of drugs, it could be computationally
expensive to use all the drug pairs during training. To solve
this issue, we develop a sampling scheme. During each
iteration of training, we use all the sensitive drugs in each
cell line but randomly sample a same number of insensitive
drugs from each respective cell line. This process is repeated
for a number of times and then the average gradient is used
to update U and V . This sampling scheme will significantly
speed up the optimization process.
4 MATERIALS
4.1 Dataset and Experimental Protocol
We use the cell line data and drug sensitivity data from
Cancer Cell Line Encyclopedia (CCLE) 8 and Cancer Ther-
apeutics Response Portal (CTRP v2) 9 (both accessed on
10/14/2016), respectively. CTRP provides the cell line re-
sponses to different drugs. The response is measured using
8. https://portals.broadinstitute.org/ccle/home
9. https://portals.broadinstitute.org/ctrp/
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TABLE 2: Dataset Description
m n #genes #AUCs #mAUCs #d/C #C/d
821 545 20,068 357,052 90,393 435 655
The columns of “m”, “n” and “#genes” have the number of cell lines, drugs and
genes in the dataset, respectively. The columns of “#AUCs” and “#mAUCs”
have the total number of available response values and missing response val-
ues, respectively. The column of “#d/C” has the average number of available
drug response values per cell line. The column of “#C/d” has the average
number of cell lines that have response values for each drug.
area-under-concentration-response curve (AUC) sensitivity
scores. Lower response (AUC) scores indicate higher drug
sensitivities. CCLE provides the expression information
over a set of genes for each of the cell lines. Larger expres-
sion values indicate higher gene expression levels. CCLE
also provides other omics data for the cell lines (e.g., copy
number variations). In this manuscript, we only use gene
expression information, as it is demonstrated as the most
pertinent to cell line response [17]. The use of other omics
data will be explored in the future research. This dataset has
large numbers of both cell lines and drugs. Table 2 presents
the description of the dataset used in the experiments. Note
that in the dataset, about 20% of the drug sensitivity values
are missing. For the drugs which do not have response
values in a cell line, we do not use the drugs in learning
the corresponding cell line latent vector.
4.1.1 Experimental Setting
We had two experimental settings for the experiments.
4.1.1.1 N-Fold Cross Validation: In the first setting,
we split drug sensitivity data for each cell line into a train-
ing and a testing set, and conduct 5-fold cross validation
to evaluate model performance. Fig. 3 demonstrates the
training-testing splits. For each cell line, its drug sensitivity
data are randomly split into 5 folds. One of the 5 folds is
used as testing set and the other four folds are used for
training. This is done 5 times, until each of the five folds
has served as testing data. The final results are the average
over the 5 folds. This experimental setting corresponds to
the application scenario in which additional drugs (i.e., the
testing data) need to be selected for each cell line/patient.
During the data split, we ensure that for each of the
drugs, there is at least one cell line in the training set that
has response information for that drug. This is to avoid the
situation in which drugs in the testing set do not have infor-
mation during training, or the use scenario in which brand-
new compounds need to be selected for further testing. The
latter will be studied in future research. We also ensure that
each cell line has drug sensitivities in the training set to
avoid the situation of brand-new cell lines. This situation
will be studied in the second experimental setting.
4.1.1.2 Leave-Out Validation: We also conduct ex-
periments in a different setting as indicated in Fig. 4, that is,
we hold out entire cell lines into the testing data so that in
training data, the held-out cell lines have no drug response
information at all. This corresponds to the use scenario to
select sensitive drugs for new cell line/new patients. Details
on how to hold out cell lines will be discussed later in
Section 5.3.
4.1.2 Sensitivity Labeling Scheme
4.1.2.1 Labeling Scheme for N-Fold Cross Valida-
tion: In the 5-fold setting (Fig. 3), for each cell line, we
use a certain percentile θ (e.g., θ=5) of all its response
values in the training set as a threshold to determine drug
sensitivity in that cell line. Thus, the sensitivity threshold is
cell line specific. It is only selected from the training data
of respective cell lines (i.e., testing data are not used to
determine the threshold as they are considered as unknown
during training). Drugs in both the training set and testing
set are then labeled as sensitive in the respective cell line
if the cell line has lower response values on the drugs than
the threshold (lower AUC scores indicate higher sensitivity),
otherwise, the drugs are labeled as insensitive. The reason
why a cell-line-specific percentile threshold is used for sen-
sitivity labeling is that there lacks a pre-defined threshold
of sensitivity scores for each of the cell lines to determine
sensitivity labels. Meanwhile, given the heterogeneity of
cell lines, we cannot apply the same threshold for different
cell lines. The idea of using sensitivity score percentile as
a threshold is very similar to that in Speyer et al. [21], in
which the outliers with low sensitivity scores are labeled as
sensitive.
4.1.2.2 Labeling Scheme for Testing New Cell Lines:
In the second setting with new cell lines (Fig. 4), since
the new cell lines have no drug response information in
training, we use a percentile threshold from the testing data
(i.e., the new cell lines; the ground truth) to label sensitivities
of the drugs in the new cell lines.
4.2 Baseline Methods
We use two strong baseline methods for comparison:
the Bayesian Multi-Task Multi-Kernel Learning (BMTMKL)
method and the Kernelized Rank Learning (KRL) method.
4.2.1 Bayesian Multi-Task Multi-Kernel Learning (BMTMKL)
BMTMKL [17], winning method for DREAM 7 challenge 10,
was originally developed to rank cell lines with respect to
10. http://dreamchallenges.org/project/dream-7-nci-dream-drug-
sensitivity-prediction-challenge/
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a drug based on their responses to the drug. In BMTMKL,
cell line ranking for each drug is considered a task. All the
cell line rankings are learned simultaneously in a multi-
task learning framework. Multiple kernels are constructed
from multiple types of omics data for cell lines to quantify
their similarities. The multi-task and multi-kernel learning
is conducted within a kernelized regression with Bayesian
inference for parameter estimation. Thus, BMTMKL predicts
drug response values via the regression and uses the values
for cell line ranking, that is, BMTMKL is a point-wise learning-
to-rank method.
Note that the drug ranking problem we are tackling in
this manuscript is a different problem compared to the cell
line ranking problem that BMTMKL is designed to tackle. The
cell line ranking problem corresponds to the application
scenario in which cell lines/patients need to be selected to
test a given drug. The drug ranking problem corresponds to
the application scenario in which drugs need to be selected
to treat a given cell line/patient. Still, BMTMKL can be used
on drug ranking problems by switching the roles of “drugs”
and “cell lines”, and the predicted drug response values can
also be used for drug ranking.
4.2.2 Kernelized Rank Learning (KRL)
KRL [13] learns a ranking structure of drugs in each cell
line by approximating the sensitivity values of drugs in the
cell line via a kernelized regression. The kernel matrix is
constructed from the gene expression profiles of cell lines.
During learning, KRL optimizes the Normalized Discounted
Cumulative Gain (NDCG@k) [10], a popular metric in learn-
ing to rank, to rank the most sensitive drugs of each cell line
among top k of the drug ranking list. Therefore, KRL is a
list-wise learning-to-rank method.
4.3 Evaluation Metrics
We first introduce the evaluation metrics that are used in
most of the experiments. Other metrics that are used in
specific experiments will be introduced later when they are
applied. The first metric that we use to evaluate the perfor-
mance of BMTMKL and pLETORg is the average-precision at k
(AP@k) [10]. It is defined as the average of precisions that
are calculated at each ranking position of sensitive drugs
that are ranked among top k in a ranking list, that is,
AP@k({di},C, f) =
k∑
j=1
Prec({d−→1 , · · · , d−→j }, C+, f) · I(d−→j ∈ C+)
k∑
j=1
I(d−→j ∈ C+)
,
(10)
where d−→j is the drug that is ranked at position j by f ,
I(d−→j ∈ C+) checks whether d−→j is sensitive in C in the
ground truth, and Prec is defined as
Prec({d⇀
1
, · · · , d−→j }, C+, f) =
j∑
i=1
I(d⇀
i
∈ C+)
/
j, (11)
that is, it is calculated as the ratio of sensitive drugs among
top-j ranked drugs. Thus, AP@k considers the ranking
positions of sensitive drugs that are ranked among top k
of a ranking list. It is a popular metric to evaluate LETOR
methods. Higher AP@k values indicate that the sensitive
drugs are ranked higher on average.
We define a second metric average-hit at k (AH@k) as the
average number of sensitive drugs that are ranked among
top k of a ranking list, that is,
AH@k({di}, C, f) =
k∑
j=1
I(d−→j ∈ C+). (12)
Higher AH@k values indicate that more sensitive drugs are
ranked among top k.
We also use CI as defined in Equation 4 to evaluate
the ranking structures among only sensitive drugs. In this
case, we denote CI specifically as sCI (i.e., CI for sensitive
drugs), and thus by default, CI evaluates the entire ranking
structures of both sensitive and insensitive drugs, and sCI
is only for sensitive drugs. Note that sCI (CI) and AP@k
measure different aspects of a ranking list. The sCI (CI)
metric measures whether the ordering structure of a ranking
list is close to its ground truth, while AP@k measures
whether the relevant instances (i.e., sensitive drugs in this
manuscript) are ranked on top. A high AP@k does not nec-
essarily indicate the ordering among the top-ranked drugs
is correct. Similarly, a high sCI (CI) does not necessarily
lead to that the most sensitive drugs being ranked on top,
particularly when there are many insensitive drugs in the
list. In this manuscript, both the drug sensitivity and the
ordering of sensitive drugs are of concern. That is, we
would like to ensure that sensitive drugs are ranked higher
than insensitive drugs, and meanwhile, the sensitive drugs
are well ordered in terms of their relative sensitivities (i.e.,
among all sensitive drugs, drugs that are more sensitive are
ranked higher than those that are less sensitive).
4.4 Gene Selection and Cell Line Similarities
We use gene expression information to measure cell line
similarities (i.e., wpq as in Equation 8) and regularize our
ranking models (i.e., wpq‖up − uq‖22 as in Equation 8). It is
well accepted that not all the genes are informative to cell
line response to drugs [17], and thus we use `1 regularized
linear regression to conduct feature selection over gene
expression data to select informative genes with respect
to each drug. It is well known that the `1 regularization
will promote sparsity in the solution, in which the non-
zero values will indicate useful independent variables (in
our case, genes). To select informative genes, the gene
expression values over all the cell lines are considered as
independent variables and the response values on each
drug from all the cell lines are considered as dependent
variables. If a cell line has no response value on a drug, the
gene expression information of that cell line is not used. A
linear least-squares regression with `1 and `2 regularization
(i.e., elastic net) is applied over these variables so as to
select informative genes for each drug. The regularization
parameters over the `1 regularizer and the `2 regularizer are
identified via regularization path [38]. Fig. S1 in the supple-
mentary materials demonstrates the regression method for
gene selection. The union of all the selected genes for all the
drugs will be used to calculate cell line similarities. In the
end, 1,203 genes are selected. The list of the selected genes
is available Section S9 in the supplementary materials. We
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TABLE 3: Performance on Ranking New Drugs
sthr method parameters performance
θ = 2
BMTMKL
αb βb usim σ AP@5 AH@5 AP@10 AH@10 sCI CI
1.0e-10 1.0e+10 RBF 10.0 0.740 1.702 0.711 2.072 0.646 0.812
KRL
k λ usim σ AP@5 AH@5 AP@10 AH@10 sCI CI
10 1.0e-06 RBF 0.001 0.753 1.784 0.725 2.137 0.673 0.702
10 1.0e-05 LIN - 0.668 1.620 0.642 2.065 0.683 0.745
pLETORg
l α β γ usim σ AP@5 AH@5 AP@10 AH@10 sCI CI
50 1.0 1.0 100.0 COS - 0.686 1.606 0.663 1.938 0.680 0.770
30 0.1 1.0 100.0 RBF 10.0 0.527 1.291 0.505 1.809 0.505 0.805
10 0.0 0.1 100.0 COS - 0.783 1.856 0.758 2.159 0.639 0.774
10 0.0 0.1 0.0 COS - 0.780 1.851 0.755 2.157 0.631 0.786
θ = 5
BMTMKL
αb βb usim σ AP@5 AH@5 AP@10 AH@10 sCI CI
1.0e-10 1.0e+10 RBF 10.0 0.828 2.736 0.772 3.761 0.652 0.812
KRL
k λ usim σ AP@5 AH@5 AP@10 AH@10 sCI CI
10 1.0e-06 RBF 0.001 0.817 2.715 0.761 3.798 0.676 0.762
10 1.0e-04 LIN - 0.789 2.580 0.730 3.690 0.689 0.756
10 1.0e-05 RBF 0.0001 0.796 2.547 0.736 3.560 0.660 0.768
pLETORg
l α β γ usim σ AP@5 AH@5 AP@10 AH@10 sCI CI
50 1.0 1.0 100.0 RBF 10.0 0.780 2.376 0.721 3.228 0.699 0.726
30 0.5 0.1 100.0 COS - 0.744 2.461 0.687 3.581 0.516 0.810
50 0.0 0.1 100.0 COS - 0.857 2.919 0.805 3.934 0.663 0.742
10 0.5 1.0 100.0 RBF 10.0 0.855 2.965 0.806 3.986 0.658 0.804
10 0.5 0.1 0.0 COS - 0.855 2.965 0.806 3.985 0.658 0.804
The columns corresponding to “αb”, “βb”, “usim”, and “σ” have the two hyperparameters, cell line similarity function, and parameter for RBF cell line similarity,
respectively, for BMTMKL. The columns corresponding to “k”, “λ”, “usim”, and “σ” have the two hyperparameters, cell line similarity function, and parameter for
RBF cell line similarity, respectively, for KRL. The columns corresponding to “l”, “α”, “β”, “γ”, “usim”, and “σ” have the latent dimension, weighting factor, latent
vector regularization parameter, cell line similarity regularization parameter, cell line similarity function, and parameter for RBF cell line similarity, respectively, for
pLETORg. The best performance of each method under each metric is in bold. The best performance of both the methods under each metric is underscored.
use cosine similarity function (COS) and radial basis function
(RBF) over the selected genes (these genes are considered as
cell line features) to calculate the similarities between cell
lines. For KRL, we also use a linear kernel (LIN), following
the experimental setting as in He et al. [13], to calculate cell
line similarities over the selected genes.
5 EXPERIMENTAL RESULTS
5.1 Ranking New Drugs
We first compare the performance of BMTMKL, KRL and
pLETORg on ranking new drugs in each cell line (i.e., ranking
testing drugs among themselves in each cell line). The
experiments follow the protocol as indicated in Fig. 3. Note
that notion of “new drugs” is with respect to each cell line,
and a new drug in a cell line could be known in a different
cell line.
We use 2 percentile (i.e., θ=2) and 5 percentile (i.e., θ=5)
as discussed in Section 4.1.2 to label sensitivity. Although
the baseline methods and pLETORg do not rely on specific
labeling schemes, the small percentiles make the drug selec-
tion problem realistic. This is because in real practice, only
the top few most sensitive drugs will be of great interest.
However, given that the sensitive drugs are few, the drug
selection problem is very non-trivial.
For the baseline methods and pLETORg we conduct a grid
search for each of their parameters, and present the results
that correspond to the best parameter combinations. The full
set of experimental results over all parameters is available
in Table S2, S3, S4, S5, S6 and S7 in the supplementary
materials. Table 3 presents the overall performance.
5.1.1 Overall Comparison
5.1.1.1 2 Percentile as Sensitivity Threshold: When
2 percentile of the response values (i.e., θ=2) in training
data is used as the sensitivity threshold, pLETORg achieves
its best AP@5 value 0.783, and it is 5.81% higher than
the best AP@5 value 0.740 of BMTMKL (p-value=3.565e-8),
and 3.98% higher than the best AP@5 value 0.753 of KRL
(p-value=9.400e-3). In terms of AP@10, pLETORg achieves
its best value 0.758, and it is 6.61% higher than 0.711 of
BMTMKL (p-value=7.994e-10) and 4.55% higher than the best
AP@10 value 0.725 of KRL (p-value=6.811e-4). Meanwhile,
pLETORg achieves higher AH@5 and AH@10 compared to
those of BMTMKL (1.856 vs 1.702, p-value=3.379e-11; 2.159 vs
2.072, p-value=5.805e-8) and compared to those of KRL (1.856
vs 1.784, p-value=2.900e-3; 2.159 vs 2.137, p-value=5.489e-
1). In particular, pLETORg achieves its best AP@k and
AH@k values when α=0.0, that is, when the push term
P ↑f in Problem 6 is the only objective to optimize. The
results demonstrate that pLETORg is strong in pushing more
sensitive drugs on top of ranking lists and thus better pri-
oritizes sensitive drugs for drug selection. On the contrary,
BMTMKL focuses on accurately predicting the response value
of each drug in each cell line. However, accurate point-
wise response prediction does not guarantee that the most
sensitive drugs are promoted onto the top of ranking lists in
BMTMKL. KRL focuses on optimizing NDCD@k among top-k
ranked drugs. However, it may heavily rely on the definition
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Fig. 6: Performance of pLETORg w.r.t. the Latent Dimension l
of the “gain” of a drug at a certain position, and thus larger
gain may not directly lead to more sensitive drugs on top.
On the other hand, pLETORg achieves an sCI value 0.639
when it achieves its best AP@k values (i.e., when l=10,
α=0.0, β=0.1 and γ=100.0 for pLETORg). Compared to the
sCI value 0.646 of BMTMKL when BMTMKL achieves its best
AP@k values, pLETORg does not outperform BMTMKL on sCI.
However, the difference is not significant (-1.08% increase;
p-value=3.117e-1). Note that when α=0.0, the ranking or-
ders among sensitive drugs are not explicitly optimized
in Problem 6. Despite this, pLETORg is able to produce
ranking orders that are very competitive to those from
BMTMKL. In terms of sCI, the best performance of pLETORg
(0.680) and the best performance of BMTMKL (0.646) are both
worse than that of KRL (0.683) (for pLETORg, -0.44% increase
with p-value=5.480e-1; for BMTMKL, -5.42% increase with p-
value=4.900e-3). Given the low AP@k and AH@k values
of KRL, this may indicate that KRL tends to sort sensitive
drugs slightly better than pLETORg and BMTMKL, but does not
necessarily rank them on top. Different from KRL, pLETORg
is able to prioritize sensitive drugs on top while maintaining
the orders among sensitive drugs reasonably well, which is
a preferred scenario in drug selection.
In addition, pLETORg achieves a CI value 0.774 together
with its best AP@k values, but BMTMKL achieves a CI value
0.812 with its best AP@k values, which is significantly better
(4.91% better than pLETORg, p-value=1.966e-123). As a mat-
ter of fact, the best CI value that pLETORg ever achieves (i.e.,
0.805 when l=30, α=0.1, β=1.0, γ=100.0) is still significantly
worse than that of BMTMKL (i.e., 0.812, p-value=4.862e-6). As
BMTMKL optimizes the predicted response values, the results
indicate that BMTMKL is able to reproduce the entire drug
ranking structures well using the predicted values. Different
from BMTMKL, pLETORg aims to push only sensitive drugs
on top of the ranking structures and optimize only the
ranking structures of those sensitive drugs (when α > 0).
Therefore, pLETORg is not able to well estimate the entire
ranking structures for both sensitive and insensitive drugs.
However, in drug selection, the top ranked drugs could
be of great interest compared to those lower-ranked drugs,
and therefore, the low CI performance of pLETORg can be
compensated by its high sCI, AP@k and AH@k values.
Compared to pLETORg and BMTMKL, KRL achieves the worst
CI (0.745). Given the fact that KRL does not model the
ranking relations among insensitive drugs, and considered
also its high sCI values and median AP@k values, this result
may indicate that KRL tends to rank some drugs that are very
insensitive higher than sensitive drugs and higher than the
drugs that are less insensitive.
5.1.1.2 5 Percentile as Sensitivity Threshold: When
5 percentile of the response values (i.e., θ=5) is used as the
sensitivity threshold, pLETORg shows similar behaviors as
in 2 percentile case. That is, in terms of AP@5, pLETORg
(0.855 when l=10, α=0.5, β=0.1 and γ=100.0; 0.857 when
l=50, α=0.0, β=0.1 and γ=100.0) outperforms BMTMKL (0.828)
at 3.26% (p-value=2.479e-6), in terms of AP@10 at 4.40%
(0.806 vs 0.772; p-value=1.511e-11), and in terms of AH@5
at 8.37% (2.965 vs 2.736; p-value=2.019e-16) and AH@10
at 5.98% (3.986 vs 3.761; p-value=2.23e-18). When pLETORg
achieves its best AP@k and AH@k, in terms of sCI, pLETORg
achieves similar performance as BMTMKL (0.658 vs 0.652; p-
value=2.500e-1), and in terms of CI, pLETORg is significantly
worse than BMTMKL (0.804 vs 0.812; p-value=3.341e-10). KRL
performs similarly at θ=5 as at θ=2, that is, on average, it is
worse than pLETORg at AP@k, AH@k and CI, but slightly
better at sCI when both achieve their optimal AP@k and
AH@k.
In particular, the AP@5 and AP@10 improvement for
pLETORg at θ=2 is larger than that at θ=5, respectively (i.e.,
5.81% vs 3.26% at AP@5, 6.61% vs 4.40% at AP@10). This
indicates that pLETORg is good at prioritizing drugs particu-
larly when there are a small number of sensitive drugs. Note
that in Table 3, for θ=2 and θ=5, the CI values in BMTMKL
are identical. This is because BMTMKL does not use labels in
training, and its performance in terms of CI does not depend
on labels. On the contrary, sCI depends on the labels as
it only measures CI within sensitive drugs. Therefore, sCI
values of BMTMKL for θ=2 and θ=5 are different. However,
pLETORg relies on labels during push and ranking in order to
learn the models, and thus, labels will affect its performance
in both CI and sCI.
In Table 3, the optimal pLETORg results always corre-
spond to non-zero γ values (i.e., the parameter on cell
line similarity regularizer in Problem 6). This indicates that
cell line similarities calculated from the gene expression
information are able to help improve the ranking of drug
sensitivities in pLETORg. The results in Table 3 also show
that the optimal performance of pLETORg is from a relatively
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small latent space with l=10. This may be due to the fact that
the sampling scheme significantly reduces the size of train-
ing instances, and thus small latent vectors are sufficient to
represent the learned information for drug prioritization.
5.1.2 Performance of pLETORg over Push Powers
Fig. 5 presents the best pLETORg performance on each of the
four metrics with respect to different push parameter α’s
when l=10 (i.e., the latent dimension corresponding to the
best AP@k values in Table 3). Fig. 5(a) and 5(b) show that in
general as α increases (i.e., decreasing emphasis on pushing
sensitive drugs on top), AP@k values decrease. When α=1.0,
that is, no push takes effect, the AP@k values become
lower than those when α < 1. This demonstrates the effect
of the push mechanism in prioritizing sensitive drugs in
pLETORg. The figures also show that the optimal sCI values
are achieved when α ∈ (0, 1), but not at α=1.0 when the
ranking structure among sensitive drugs is the only focus.
This is probably due to that the ranking difference between
sensitive and insensitive drugs involved in the push term
P ↑f can also help improve the ranking among sensitive
drugs. In addition, the figures show that the optimal CI
values are achieved when α ∈ (0, 1). This is because with
very small α values, sensitive drugs are strongly pushed
but it does not necessarily result in good ranking structures
among all sensitive and insensitive drugs. Similarly, when
α is very large, the ranking structures among only sensitive
drugs are highly optimized, which does not necessarily lead
to good ranking structures among all drugs either. Thus,
the best overall ranking structures are achieved under a
combinatorial effect of both the push and the sensitive drug
ranking.
5.1.3 Performance of pLETORg over Latent Dimensions
Fig. 6 presents the best pLETORg performance on each of
the four metrics with respect to different latent dimension
l. Fig. 6(a) and 6(b) show that in general, small latent
dimensions (e.g., l in 10 to 15) are sufficient in order to
achieve good results on drug ranking. We interpret each
dimension in the drug latent vectors and cell line latent
vectors as to represent a certain latent feature that together
determine drug rankings in each cell line. Thus, the small
latent dimensions indicate that the learned latent vectors
are able to capture latent features that are specific to drugs
and cell lines.
On the other hand, as AP@k tends to decrease as l
increases, sCI tends to increase. This indicates that larger
l may enable better rankings among sensitive drugs, but not
necessarily pushing sensitive drugs on top. Fig. 6 also shows
that CI first increases and then decreases as l becomes larger,
following an opposite trend of sCI. This demonstrates that
good ranking structures among all the drugs do not directly
indicate good ranking structures among sensitive drugs,
and vice versa. We also notice that with α=0.5, pLETORg has
better AP@k as l increases from 30 to 50. This is probably
because sufficiently large latent dimensions could also cap-
ture the drug sensitivity information when the sensitivity
threshold is relaxed (i.e., more drugs are considered as
sensitive when θ=5 than those when θ=2). Even though,
pLETORg still performs better at l=10 than at l=50 with θ=5.
Considering computational costs, we do not explore other
even larger latent dimensions.
5.2 Ranking New and Known Drugs
We evaluate the performance of pLETORg on ranking both
new drugs (i.e., testing drugs) and known drugs (i.e., train-
ing drugs) together in the experimental setting as in Fig. 3.
This corresponds to the use scenario in which new drugs
need to be compared with known drugs so as to select the
most promising drugs among all available (i.e., both new
and known) drugs. In this case, we focus on evaluating
whether most of the true sensitive drugs can be prioritized.
5.2.1 Evaluation Metrics
The evaluation is based on the following two specific met-
rics. The first metric, denoted as AT@k, measures among
the top-k most sensitive drugs of each cell line in the
ground truth (including both training and testing drugs),
what percentage of them are ranked still among top k in the
prediction, that is,
AT@k({di}, C, f) =
∑
dj∈top-k(C)
I(d−→j ∈ top-k(C))
k
, (13)
where d−→j is the drug that is ranked at position j by f , and
top-k(C) is the set of top-k most sensitive drugs in cell line
C.
The second metric, denoted as NT@k, measures among
the new drugs that should be among the top-k most sen-
sitive drugs of each cell line in the ground truth, what
percentage of them are ranked actually among top k in the
prediction, that is,
NT@k({di}, C, f) =
∑
dj is new
I(d−→j ∈ top-k(C))∑
dj is new
I(dj ∈ top-k(C))
. (14)
The reason why AP@k and AH@k are not used in this
experimental setting is that they can be easily dominated
by known drugs (i.e., training data). This is because they
are defined for top-k ranked drugs. It is very likely that
the top-k ranked drugs, when known and new drugs are
considered together, are actually known drugs since they
are explicitly optimized to be on top during the training
process (for pLETORg and KRL). Different from AP@k and
AH@k, AT@k and NT@k are defined as particular ratios
over the sensitive drugs, which are from both training and
testing data in this case, and thus less biased by the training
data.
5.2.2 Overall Comparison
Table 4 presents top performance of BMTMKL, KRL and
pLETORg in terms of AT@k and NT@k. The full set of
experimental results is available in Table S8, S9, S10, S11,
S12, and S13 in the supplementary materials. The results
in Table 4 show that in terms of NT@k, pLETORg is able
to achieve very similar results (when l=5) as BMTMKL and
KRL, in which cases, pLETORg even achieves slightly better
results on AT@k than BMTMKL and KRL when both BMTMKL
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TABLE 4: Performance on Ranking New and Known Drugs (%)
sthr method parameters performance
- BMTMKL
αb βb usim σ AT@5 AT@10 NT@5 NT@10
1.0e0 1.0e0 RBF 10.0 48.03 54.57 47.57 54.00
1.0e-10 1.0e-10 RBF 10.0 47.99 54.49 47.62 54.01
θ = 2
KRL
k λ usim σ AT@5 AT@10 NT@5 NT@10
10 1.0e-06 RBF 0.01 78.88 78.24 3.43 28.51
10 50 LIN - 45.64 51.44 45.99 51.81
10 1.0e-06 RBF 0.0001 45.63 51.88 45.55 52.28
pLETORg
l α β γ usim σ AT@5 AT@10 NT@5 NT@10
50 0.50 0.1 1.0 RBF 10.0 71.38 64.27 3.83 9.29
50 0.10 1.0 10.0 COS - 62.92 65.41 0.69 2.00
5 0.10 0.1 100.0 RBF 10.0 49.84 58.47 46.68 55.60
5 0.05 0.1 100.0 RBF 10.0 49.66 58.47 46.53 55.71
θ = 5
KRL
k λ usim σ AT@5 AT@10 NT@5 NT@10
10 1.0e-06 RBF 0.01 75.97 75.07 2.64 4.14
10 1.0e-04 LIN - 48.25 54.54 46.42 54.51
pLETORg
l α β γ usim σ AT@5 AT@10 NT@5 NT@10
50 1.00 0.1 10.0 COS - 79.42 76.49 16.99 36.06
50 0.50 0.1 100.0 COS - 74.93 77.36 5.67 17.29
5 0.50 0.1 10.0 RBF 10.0 49.84 57.97 45.50 54.86
The columns corresponding to “αb”, “βb”, “usim”, and “σ” have the two hyperparameters, cell line similarity function, and parameter for RBF cell line similarity,
respectively, for BMTMKL. The columns corresponding to “k”, “λ”, “usim”, and “σ” have the two hyperparameters, cell line similarity function, and parameter for
RBF cell line similarity, respectively, for KRL. The columns corresponding to “l”, “α”, “β”, “γ”, “usim”, and “σ” have the latent dimension, weighting factor, latent
vector regularization parameter, cell line similarity regularization parameter, cell line similarity function, and parameter for RBF cell line similarity, respectively, for
pLETORg. The best performance of each method under each metric is in bold. The best performance of both the methods under each metric is underscored.
and KRL achieve their best NT@k. This demonstrates that
pLETORg has similar power as BMTMKL and KRL in ranking
new and known sensitive drugs together, and even slightly
better power in prioritizing new sensitive drugs. In terms
of AT@k, pLETORg is able to achieve much better results
(when l=50) than BMTMKL. However, when pLETORg achieves
high AT@k, the corresponding NT@k is not optimal. Since
the majority of top-k most sensitive drugs among both
new and known drugs will be known drugs, the good
performance of pLETORg on AT@k validates that the push
mechanism in pLETORg takes place during training. In
addition, pLETORg outperforms KRL in terms of AT@k when
θ=5, but is significantly worse than KRL when θ=2. This
indicates potential overfitting of KRL in ranking sensitive
drugs on top during training, particularly when sensitive
training drugs are limited (θ=2) (again, sensitive training
drugs will be the majority of sensitive drugs).
5.3 Ranking Drugs in New Cell Lines
In this section, we present the experimental results on
ranking drugs in new cell lines. The experiments follow the
experimental setting as in Fig. 4.
5.3.1 Analysis on Cell Line Similarities
New cell lines don’t have any drug response information or
latent vectors, and the only information that can be lever-
aged in order to select drugs for them is their own genomics
information. Therefore, we first validate whether we can use
the gene expression information for drug selection in new
cell lines in pLETORg.
We first calculate the similarities of cell lines using their
latent vectors learned from pLETORg (in the setting of Fig. 3)
in RBF function. The correlation between such similarities
and the cell line similarities calculated from gene expres-
sions (i.e., wpq as in Equation 8) using RBF function is 0.426.
The correlations show that cell line gene expression sim-
ilarities and their latent vector similarities are moderately
correlated. We further analyze the cell lines whose gene
expression similarities (using RBF function) are among 90
percentile. For each of such cell lines, we identify 10 most
similar cell lines in their gene expressions. Fig. S2 in the
supplementary materials shows the gene expression similar-
ities of all such cell lines and their latent vector similarities.
Fig. S2 in the supplementary materials demonstrates that for
those cell lines whose gene expression similarities are high,
their latent vector similarities are also significantly higher
than average (the average cell line latent vector similarity
is 0.682). This indicates the feasibility of using high gene
expression similarities to connect new cell lines with cell
lines used in pLETORg
5.3.2 Experimental Setting
Based on the analysis on cell line similarities, we split testing
cell lines (i.e., new cell lines) from training cell lines (as in
Fig. 4) such that each of the testing cell lines has sufficient
number of similar training cell lines in terms of their gene
expressions. Cell line latent vectors are learned in pLETORg
only for those training cell lines, and drug latent vectors are
learned for all the drugs. Note that the label scheme in this
setting follows that in Section 4.1.2.2. The detailed protocol
is available in Section S5 in supplementary materials.
In order to select sensitive drugs for each of the test-
ing/new cell lines, we first generate a latent vector for the
testing cell line as the weighted sum of latent vectors of its
top-10 most similar (in gene expressions) training cell lines.
The weights are the respective gene expression similarities.
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TABLE 5: Performance on Selecting Drugs for New Cell Lines
sthr method AP@5 AP@10
50 100 150 200 250 300 350 400 50 100 150 200 250 300 350 400
θ = 2
BMTMKL 0.855 0.842 0.844 0.834 0.833 0.829 0.823 0.829 0.792 0.783 0.783 0.778 0.774 0.768 0.763 0.768
KRL 0.451 0.409 0.399 0.432 0.430 0.388 0.397 0.382 0.436 0.403 0.390 0.398 0.404 0.379 0.377 0.356
pLETORg 0.876 0.870 0.870 0.852 0.861 0.856 0.848 0.853 0.800 0.770 0.789 0.777 0.798 0.780 0.771 0.792
50 100 150 200 250 300 350 400 50 100 150 200 250 300 350 400
θ = 5
BMTMKL 0.951 0.945 0.946 0.937 0.940 0.937 0.935 0.938 0.903 0.908 0.911 0.907 0.908 0.906 0.903 0.906
KRL 0.621 0.568 0.565 0.545 0.565 0.570 0.549 0.543 0.573 0.497 0.524 0.501 0.520 0.503 0.515 0.502
pLETORg 0.965 0.958 0.955 0.949 0.949 0.949 0.947 0.947 0.908 0.908 0.908 0.906 0.904 0.906 0.901 0.906
The columns corresponding to “AP@5” and “AP@10” have the AP@5 and AP@10 evaluation values of the corresponding methods, respectively. The columns
corresponding to “50” · · · “400” have the number of new cell lines in the experiment (i.e., Nnew). The best performance of the three methods under each metric is
in bold.
The drugs are then scored using the latent vector of the new
cell line and latent vectors of all drugs.
5.3.3 Overall Comparison
Table. 5 presents the performance of BMTMKL, KRL and
pLETORg with respect to different numbers of new cell lines,
denoted as Nnew, in terms of AP@5, AP@10, respectively.
We don’t present the performance in sCI and CI here
because in drug selection for new cell lines/patients, CI is
not practically as indicative as AP@k, particularly in drug
selection from a large collection of drugs. For each of the
two evaluation metrics, we compare the performance of
BMTMKL, KRL and pLETORg when θ=2 and θ=5. Note that as
Nnew increases (i.e., more new cell lines), the average gene
expression similarities between new cell lines and training
cell lines decrease according to the data split protocol.
Table. 5 shows that as Nnew increases, the AP@5 and
AP@10 values of pLETORg, KRL and pLETORg with both
θ=2 and θ=5 decrease in general. This is because as more
cell lines are split into testing set, on average, training cell
lines and testing cell lines are less similar, and thus it is
less accurate to extrapolate from training cell lines to new
cell lines. Even though, pLETORg consistently outperforms
BMTMKL and KRL over all Nnew values in terms of AP@5.
and performs similarly to BMTMKL and still outperforms KRL
in terms of AP@10. Specifically, when 50 cell lines are held
out for testing (i.e., Nnew=50), pLETORg achieves AP@5 =
0.876/0.965 when θ = 2/5, compared to AP@5 = 0.855/0.951
of BMTMKL and AP@5 = 0.451/0.621 of KRL. When 400 cell
lines are held out for testing, pLETORg achieves AP@5 =
0.853/0.947, compared to AP@5 = 0.829/0.938 of BMTMKL
and AP@5 = 0.382/0.543 of KRL when θ=2/5. Particularly,
with θ=2, pLETORg outperforms BMTMKL at 2.5% when
Nnew=50, and at 2.9% when Nnew=400. This indicates that
when the drug selection for new cell lines is more diffi-
cult (e.g., fewer training cell lines, fewer sensitive drugs),
pLETORg outperforms BMTMKL more. Also with θ=2, when
more cell lines are held out (Nnew ≥ 250), pLETORg out-
performs BMTMKL in AP@10. For example, when Nnew=250,
pLETORg achieves AP@10 = 0.798, compared to AP@10 =
0.774 of BMTMKL. This also indicates that pLETORg outper-
forms pLETORg on more difficult drug selection problems.
Please note that KRL performs significantly worse than
pLETORg and BMTMKL in selecting drugs for new cell lines.
This might be due to similar reasons as discussed in Sec-
tion 5.2.2, that is, KRL tends to overfit the known (training)
cell lines and is not well generalizable to new cell lines.
5.4 Analysis on Latent Vectors
5.4.1 Analysis on Drug Latent Vectors
5.4.1.1 Evaluation Measurements: We evaluate how
much the learned drug latent vectors could be interpreted
in differentiating sensitive drugs and insensitive drugs. To
have quantitative measurements for such an evaluation, we
calculate the following four types of measurement:
1) the cosine similarities of drugs using their latent vectors
learned from pLETORg, denoted as COSL;
2) the Tanimoto coefficients [39] of drugs using their AF
features 11, denoted as TANAF;
3) the average ranking percentile difference for all the drug
pairs over all the cell lines in the ground truth, denoted
as ∆r%; and
4) the average difference of responsive cell line ratios for
drug pairs over all the cell lines in the ground truth,
denoted as ∆e%.
AF features are binary fingerprints representing whether a
certain substructure is present or not in a drug. Thus, the
Tanimoto coefficients over AF features measure how drugs
are similar in terms of their intrinsic structures (Tanimoto co-
efficient has been demonstrated to be effective in comparing
drug structures [39]). The measurement ∆r% is calculated
on all pairs of drugs over the cell lines that both of the drugs
in a pair have sensitivity measurement (i.e., no missing
values on either of the drugs) in the cell lines. The absolute
values of the percentile ranking differences over such cell
lines are then averaged into ∆r%. The measurement ∆e% is
calculated as the percentage of cell lines in which a drug is
sensitive (with θ=5). The absolute values of such ratio differ-
ences from all the drug pairs are then averaged into ∆e%.
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Fig. 7: ∆r% in different drug pairs
5.4.1.2 Discriminant Power of Drug Latent Vectors:
We group all the drug pairs based on their COSL and TANAF
percentile values. Fig. 7 presents the ∆r% for different
groups of drug pairs. In Fig. 7, the colors code the ∆r%
11. http://glaros.dtc.umn.edu/gkhome/afgen/overview
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values. The two values in each drug group (e.g., x/y in
each cell in the figure) are the average percentile ranking
of the higher-ranked drugs (i.e., x) and of the lower-ranked
drugs (i.e., y) in the drug pairs, respectively. The difference
of the two values in each drug group is the corresponding
∆r%. Fig. 7 shows that when the drugs are less similar
in their latent vectors (i.e., smaller COSL percentile; the left
columns in Fig. 7), the drugs are ranked more differently
among cell lines on average (i.e., larger ∆r% values). Drugs
with similar latent vectors tend to be ranked similarly (i.e.,
smaller ∆r% values in the right columns in Fig. 7 with larger
COSL percentiles). This indicates that the drug latent vectors
learned from pLETORg are able to encode information that
differentiates drug rankings in cell lines.
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Fig. 8: ∆e% in different drug pairs
Fig. 8 presents the ∆e% for different groups of drug
pairs. In Fig. 8, the colors code the ∆e% values. The two val-
ues in each drug group (e.g., x/y) are the average responsive
cell line ratio of the higher-ranked drugs (i.e., x) and of the
lower-ranked drugs (i.e., y) in the drug pairs, respectively.
The difference of the two values in each drug group is the
corresponding ∆e%. Fig. 8 shows that drugs that are very
different from others in COSL (i.e., smaller COSL percentile;
the left columns in Fig. 8) are sensitive in more cell lines (i.e.,
larger x in x/y values of the left columns). Specifically, the
higher-ranked drugs (i.e., corresponding to x in x/y values
in Fig. 8) in the 4 ranges of COSL values (in increasing order)
are sensitive in 28.8%, 4.7%, 1.3% and 0.4% of the cell lines
on average, respectively. This also corresponds with what
Fig. 7 shows, that is, drugs that are more different from
others in COSL tend to be ranked higher than the drugs that
are more similar to others in COSL. Specifically, in Fig. 7,
the higher-ranked drugs (i.e., corresponding to x in x/y
values in Fig. 7) in the 4 ranges of COSL values (in increasing
order) are ranked at 82.2, 61.9, 54.7 and 47.6 percentile on
average, respectively. These indicate that the sensitive drugs
are better differentiated in drug latent vectors, and thus
pLETORg is effective in deriving drug latent vectors that are
specific to drug sensitivities.
5.4.1.3 Drug Latent Vectors as New Drug Features:
Analysis on drug latent vectors as new drug features is
available in Section S6 in the supplementary materials.
5.4.1.4 Interpretability of Drug Latent Vectors:
Analysis on the interpretability of drug latent vectors is
available in Section S7 in the supplementary materials.
5.4.2 Analysis on Cell Line Latent Vectors
Fig. 9 presents the correlations among three different types
of cell line similarities within each of the tumor types.
The three cell line similarities are calculated from gene
expressions (GE) using RBF function on the 1,203 selected
genes, cell line latent vectors (LV) using RBF function and
drug sensitivity profiles (DS) using Spearman rank cor-
relation coefficient. The three corresponding correlations
are denoted as corr(GE, LV), corr(GE, DS) and corr(LV, DS),
respectively. The numbers associated with tumor types in
Fig. 9 indicate the number of cell lines of corresponding
tumor types. (e.g., melanoma (51) indicates that there are
51 cell lines of melanoma). Among the 37 tumor types as
originally categorized in CCLE, 28 tumor types (i.e., 75.7%
of all tumor types) have their corr(LV, DS) higher than or
same as corr(GE, DS), and the average percentage difference
is 59.9%. For example, for 15 neuroblastoma cell lines,
corr(LV, DS) is on average 191.7% higher than corr(GE, DS).
For all the cell lines of various lymphoma, corr(LV, DS) is on
average at least 20% higher than corr(GE, DS). This indicates
that even when the correlation between gene expression
and drug sensitivity is not strong, through learning cell line
latent vectors, pLETORg can discover novel cell line features
(i.e., cell line latent vectors) that better characterize their
drug response patterns. As a matter of fact, the improve-
ment of corr(LV, DS) over corr(GE, DS) is more significant
when corr(GE, DS) is lower (i.e., the left side of the panel in
Fig. 9). This indicates pLETORg may be effective for cell lines
which do not have significant correlation between selected
gene expression and drug sensitivity profiles. For the cell
lines whose corr(GE, DS) is large (i.e., the right side of the
panel in Fig. 9), corr(LV, DS) is still high in general and
meanwhile corr(GE, LV) is also high. This indicates that
pLETORg may be effective in retaining the useful signals
from gene expression when the correlation between selected
gene expression and drug sensitivity profiles is strong. For
a few tumor types with relatively low corr(GE, LV) (e.g.,
liver, AML and esophagus), their corr(LV, DS) is actually rel-
atively high. This may indicate the capability of pLETORg in
learning new signals for cell lines by leveraging information
from multiple other cell lines.
6 DISCUSSIONS AND CONCLUSIONS
We developed genomics-regularized joint push and
learning-to-rank method pLETORg to tackle cancer drug
selection for three particular application scenarios: 1). select
sensitive drugs from new drugs for each known cell line;
2). select sensitive drugs from all available drugs including
new and known drugs for each known cell line; and 3).
select sensitive drugs from all available drugs for new cell
lines. Our new method pLETORg outperforms or achieve
similar performance to the state-of-the-art methods BMTMKL
and KRL. Note that BMTMKL was originally developed to
select cell lines for drugs. However, BMTMKL uses kernel
regression and approximates drug response values to sort
cell lines. Such drug response values can also be used to
select drugs for cell lines, as we used in this manuscript.
KRL was originally developed to select drugs for cell lines –
the same goal as our pLETORg, but shows low generalization
capabilities in selecting drugs for new cell lines and from
new drugs.
pLETORg is a pair-wise learning-to-rank method which
scores each drug in each cell line using latent vectors and
ranks drugs based on the latent scores. This is fundamen-
tally different from BMTMKL (a point-wise learning-to-rank
method) and KRL (a list-wise learning-to-rank method), in
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Fig. 9: Correlation among Different Cell Line Similarities
which the drug response values are approximated and used
to sort drugs. The latent scores enable more flexibility to
learn accurate drug ranking structures, but fall short when
drug response values are also of concerns. We will inves-
tigate a combination of latent scoring and drug response
value regression to leverage the advantages of both the
schemes.
In pLETORg, each drug has a global latent vector which
is the same in all cell lines. This might be restrictive as the
learned drug latent vectors may have to compromise their
performance in some cell lines in order to achieve better
performance in other cell lines, and thus better overall per-
formance. We will explore personalized drug latent vectors
in the future research, that is, each drug will have different
latent vectors with respect to different cell lines. In this way,
the ranking performance on each cell line is expected to be
further improved.
In addition, in pLETORg and BMTMKL, gene selection has
been done across all tissue types/origins for all the cell lines
together. However, different tissue types/origins may have
different genes useful in their drug rankings. Therefore,
global gene selection may end up with genes which tend to
be globally indicative for assessing drug sensitivities, while
locally informative gene information has been neglected.
We will explore localized gene selection in the future re-
search, by clustering cell lines based on tissues/origins and
conducting gene selection over each cluster. We will also
explore cell line clustering with respect to their drug ranking
structures. It is expected that by localized gene selection,
drug selection could be more accurate for each cell line.
The pLETORg method suffers from the lack of inter-
pretability. It is not easy to explain what each of the
drug/cell line latent dimensions represents or whether they
correlate to any mechanisms of actions. This is because the
latent vectors are learned only with respect to the goal of
optimizing the drug ranking structures, without any poten-
tial MOA (if ever known) or causal features (if ever known)
explicitly modeled. We would tackle this challenging in-
terpretability issue in the future research, for example, by
integrating known knowledge in the latent vector learning.
We will also evaluate our pLETORg method on other
drug-cell line screening data, for example, NCI60 12 and
LINCS-L1000 13 data. When the number of drugs (chemi-
cal compounds in LINCS-L1000) is large, it becomes more
challenging computationally when pairs of drugs are used
in learning. We will explore fast learning algorithms to learn
drug latent vectors in the future research.
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